Bristol-Myers Squibb, among the least active of Big Pharma players in emerging markets so far, is starting to make some moves--at least in China. Bristol-Myers has entered a collaboration on Orencia SC with Simcere Pharmaceutical Group, its second China-related partnership this year.
Thanks to some big-name deals over the past year, Ambrx could rake in nearly $1 billion in licensing for its antibody drug conjugates, but the company hasn't lost sight of its in-house development, now partnering with WuXi PharmaTech and a Chinese drugmaker to advance a breast cancer treatment.
Novartis acknowledged this week it had terminated some sales execs in India as it probes unethical practices there, and now GlaxoSmithKline admits it is looking into whether its sales folks have been bribing doctors in China.
While Thermo Fisher is busy raising cash to seal its $13.6 billion fate, Life Technologies is expanding its heft in South Korea, buying up another distributor in the growing market.
GlaxoSmithKline fired Jingwu Zang after allegations that the R&D shop he helmed in China published falsified data. Yet Zang has fired back in a report from The Wall Street Journal, saying that he played a supervisory role and had no part in the actual misrepresentations that appeared in a 2010 issue of Nature Medicine .
Just weeks after the FDA issued a ban on products from a Wockhardt plant, another Indian company, RPG Life Sciences, has been issued a warning that accuses it of backdating worksheets, selectively reporting test results and destroying some records of out-of-spec test findings.
Malaria parasites remain the scourge of Africa and other tropical parts of the developing world. But Case Western Reserve University scientists say the use of magnets might be a low-cost way to diagnose the infection, enabling quicker treatment on a global level.
Schott Pharmaceutical Systems is set to expand its pharmaceutical primary packaging site, announcing plans to invest in the "mid-double-digit-million euro range" in its Hungarian site in Lukácsháza.
There has been a significant amount of M&A in the contract drug manufacturing sector, and established players are investing to get their piece of the growth as well. Canada's Patheon is now reaping the rewards of its own decision to expand.
Lots of drug companies have been pointing to growth in emerging markets as a bright spot in their earnings reports. Now, Patheon can not only say it has seen growth from investments in new markets, but that they provided it with a return to a profit, however small.